| 22.04.2024 09:30 | HCM | Vesting of Awards Under the LTIP | RNS |
| 08.04.2024 09:30 | HCM | 2023 Annual Report and Notice of AGM | RNS |
| 05.04.2024 09:30 | HCM | Data to be Presented at AACR Congress 2024 | Reach |
| 02.04.2024 10:32 | HCM | Hutchmed endometrial cancer treatment application accepted for review | Alliance |
| 02.04.2024 07:00 | HCM | HUTCHMED and Innovent Announce NDA Acceptance | Reach |
| 28.03.2024 11:08 | HCM | Hutchmed lung cancer treatment accepted for review in China | Alliance |
| 28.03.2024 07:00 | HCM | Savolitinib sNDA Accepted in China | Reach |
| 22.03.2024 10:09 | HCM | Hutchmed begins registration stage for sovleplenib phase 2/3 trial | Alliance |
| 22.03.2024 07:00 | HCM | Initiation of Registration Stage of P2/3 Trial | Reach |
| 14.03.2024 09:00 | HCM | LTIP and Share Option Scheme | RNS |
| 05.03.2024 08:30 | HCM | Vesting of awards under the LTIP | RNS |
| 28.02.2024 17:31 | TRIG, AIQ, CRV | EARNINGS: Hutchmed revenue surges, Craven House's loss widens | Alliance |
| 28.02.2024 12:45 | HCM | Publication of Form 20-F | Reach |
| 28.02.2024 11:30 | HCM | 2023 Full Year Results and Business Updates | RNS |
| 21.02.2024 15:14 | STJ, RHIM, TRIG | UK earnings, trading statements calendar - next 7 days | Alliance |
| 07.02.2024 09:50 | HCM | Hutchmed hails fruquintinib trial results for gastric cancer treatment | Alliance |
| 07.02.2024 07:00 | HCM | Presentation of Phase III Data on Fruquintinib | Reach |
| 02.02.2024 09:52 | HCM | Hutchmed says Inmagene exercises option to licence drug candidates | Alliance |
| 30.01.2024 09:20 | HCM | Hutchmed celebrates cancer drug approval in hometown of Hong Kong | Alliance |
| 30.01.2024 07:12 | HCM | HUTCHMED Receives Marketing Approval in Hong Kong | Reach |
| 11.01.2024 10:17 | HCM | TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau | Alliance |
| 11.01.2024 07:00 | HCM | Sovleplenib NDA Granted Priority Review in China | Reach |
| 29.12.2023 08:30 | HCM | Total Voting Rights | RNS |
| 29.12.2023 08:30 | HCM | Blocklisting Six Monthly Return | RNS |
| 21.12.2023 11:36 | HCM | IN BRIEF: Hutchmed China renews deals with "substantial" shareholders | Alliance |
| 21.12.2023 10:00 | HCM | Overseas Regulatory Announcement | RNS |
| 13.12.2023 13:56 | HCM | Hutchmed completes enrolment for fruquintinib trial | Alliance |
| 13.12.2023 07:00 | HCM | Inclusion in National Reimbursement Drug List | Reach |
| 13.12.2023 07:00 | HCM | Completed Enrollment of Phase II/III Trial | Reach |
| 07.12.2023 10:04 | HCM | Overseas Regulatory Announcement | RNS |
| 01.12.2023 07:00 | HCM | Clinical Data to be Presented at Congresses | Reach |
| 30.11.2023 08:30 | HCM | Total Voting Rights | RNS |
| 09.11.2023 12:16 | HCM | Hutchmed hails Takeda's fruquintinib approval from US for cancer form | Alliance |
| 09.11.2023 07:00 | HCM | U.S. FDA Approval of FRUZAQLA™ (fruquintinib) | RNS |
| 24.10.2023 09:30 | HCM | Vesting of awards under the LTIP | RNS |
| 16.10.2023 09:30 | HCM | Clinical Data to be Presented at ESMO 2023 | Reach |
| 29.09.2023 10:12 | HCM | Hutchmed notes Takeda submits fruquintinib drug application in Japan | Alliance |
| 29.09.2023 09:30 | HCM | NDA Submission for Fruquintinib in Japan | Reach |
| 29.09.2023 09:30 | HCM | Total Voting Rights | RNS |
| 14.09.2023 09:30 | HCM | Director’s Share Dealing | RNS |
| 12.09.2023 10:26 | HCM | IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat | Alliance |
| 12.09.2023 09:30 | HCM | Phase IIIb Savolitinib Results at WCLC 2023 | Reach |
| 12.09.2023 07:00 | HCM | Patient Enrollment Completed for Bridging Study | Reach |
| 31.08.2023 09:30 | HCM | Total Voting Rights | RNS |
| 29.08.2023 09:30 | HCM | IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag | Alliance |
| 29.08.2023 07:00 | HCM | BTD in China for Savolitinib for Gastric Cancer | Reach |
| 21.08.2023 08:46 | HCM | Hutchmed China hails trial on sovleplenib meeting primary endpoint | Alliance |
| 21.08.2023 07:00 | HCM | Sovleplenib Phase 3 Study Meets Primary Endpoint | RNS |
| 07.08.2023 09:30 | HCM | Exercise of Share Options by a Director | RNS |
| 31.07.2023 12:47 | HCM | Hutchmed swings to profit after "sharpening goals and priorities" | Alliance |
| 31.07.2023 12:00 | HCM | Interim Results and Business Updates | RNS |
| 24.07.2023 15:46 | SXS, QTX, PODP | UK earnings, trading statements calendar - next 7 days | Alliance |
| 20.07.2023 14:14 | HCM | IN BRIEF: Hutchmed progresses fruquintinib designation and testing | Alliance |
| 20.07.2023 07:00 | HCM | Breakthrough Therapy Designation for Fruquintinib | Reach |
| 13.07.2023 09:30 | HCM | Changes to Board and Technical Committee | RNS |
| 10.07.2023 08:53 | HCM | IN BRIEF: Hutchmed starts study for tumour treatment in China | Alliance |
| 10.07.2023 07:00 | HCM | Phase 1 Study of HMPL-415 Initiated | Reach |
| 29.06.2023 09:30 | HCM | Blocklisting Six Monthly Return | RNS |
| 26.06.2023 09:30 | HCM | HUTCHMED to Announce 2023 Half-Year Results | RNS |
| 16.06.2023 08:51 | HCM | Hutchmed, Takeda Fresco-2 study published in The Lancet | Alliance |
| 16.06.2023 07:00 | HCM | Phase III FRESCO-2 Results in The Lancet | RNS |
| 15.06.2023 16:51 | HCM | IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug | Alliance |
| 15.06.2023 15:39 | HCM | MAA of Fruquintinib Validated by the EMA | RNS |
| 09.06.2023 10:30 | HCM | HUTCHMED Highlights Presentations at EHA and ICML | Reach |
| 06.06.2023 10:00 | HCM | LTIP and Share Option Scheme | RNS |
| 31.05.2023 09:30 | HCM | Total Voting Rights | RNS |
| 26.05.2023 08:56 | HCM | Hutchmed China celebrates FDA review, teases new data at ASCO meeting | Alliance |
| 26.05.2023 07:00 | HCM | Fruquintinib NDA Granted Priority Review by FDA | RNS |
| 26.05.2023 07:00 | HCM | HUTCHMED Highlights Presentations at ASCO 2023 | Reach |
| 17.05.2023 09:30 | HCM | Standard form for notification of major holdings | RNS |
| 12.05.2023 13:15 | HCM | Annual General Meeting Poll Results | RNS |
| 12.05.2023 09:30 | HCM | Board of Directors and Board Committee Membership | RNS |
| 10.05.2023 09:30 | HCM | Appointment of Independent NED | RNS |
| 05.05.2023 15:57 | WPM, ITIM, HCM | UK shareholder meetings calendar - next 7 days | Alliance |
| 28.04.2023 09:30 | HCM | Total Voting Rights | RNS |
